Biotech News
MannKind Reports First Quarter 2026 Financial Results and Provides Business Update
investors.mannkindcorp.com2026-05-06 20:02 EST
Q1 updates: Q1 2026 total revenues of $90.2M, +15% vs. Q1 2025 Built out launch infrastructure and aligned field-based teams for upcoming launches Settlement of senior convertible notes of $36.3M Program updates: Afrezza ® pediatric indication PDUFA date May 29, 2026 Furoscix ReadyFlow ™